Patents by Inventor Travis Karg

Travis Karg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-Mammalian RAS Transgenic Animal Model
    Publication number: 20200390074
    Abstract: Non-mammalian, transgenic animals, e.g., flies, that include a RAS transgene, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, such as neoplastic, diseases.
    Type: Application
    Filed: April 21, 2020
    Publication date: December 17, 2020
    Inventors: Travis Karg, William A. Garland, Steve Yanofsky
  • Non-mammalian RAS transgenic animal model
    Patent number: 10660318
    Abstract: Non-mammalian, transgenic animals, e.g., flies, that include a RAS transgene, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, such as neoplastic, diseases.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: May 26, 2020
    Assignee: Tosk, Inc.
    Inventors: Travis Karg, William A. Garland, Steve Yanofsky
  • Non-Mammalian RAS Transgenic Animal Model
    Publication number: 20160249593
    Abstract: Non-mammalian, transgenic animals, e.g., flies, that include a RAS transgene, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, such as neoplastic, diseases.
    Type: Application
    Filed: August 19, 2014
    Publication date: September 1, 2016
    Inventors: Travis Karg, William A. Garland, Steve Yanofsky
  • Methotrexate adjuvants to reduce toxicity and methods for using the same
    Patent number: 9382287
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: July 5, 2016
    Assignee: Tosk, Inc.
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg
  • Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same
    Publication number: 20150072945
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Application
    Filed: October 6, 2014
    Publication date: March 12, 2015
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg
  • Methotrexate adjuvants to reduce toxicity and methods for using the same
    Patent number: 8853227
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: October 7, 2014
    Assignee: Tosk, Incorporated
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg
  • Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same
    Publication number: 20110319419
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Application
    Filed: June 20, 2011
    Publication date: December 29, 2011
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg
  • Methotrexate adjuvants to reduce toxicity and methods for using the same
    Patent number: 7998967
    Abstract: Methods are provided for using methotrexate (MTX) in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of MTX in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: August 16, 2011
    Assignee: Tosk, Incorporated
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg
  • METHOTREXATE ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME
    Publication number: 20090325969
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Application
    Filed: March 2, 2009
    Publication date: December 31, 2009
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg, Todd Wipke, Joseph Konopelski
  • Methotrexate adjuvants to reduce toxicity and methods for using the same
    Patent number: RE48253
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: October 13, 2020
    Assignee: Tosk, Inc.
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg